Literature DB >> 17579280

Clinical and laboratory examinations in the subgroups of chronic urticaria.

Beatrix Irinyi1, György Széles, Edit Gyimesi, Judit Tumpek, Emese Herédi, Georgitsis Dimitrios, Róza Adány, János Hunyadi, Andrea Szegedi.   

Abstract

BACKGROUND: The aetiology of chronic urticaria is heterogeneous. Physical urticaria (PU) is estimated at around 35%, autoimmune urticaria (AIU) at 25% and chronic idiopathic urticaria (CIU) at 35% of all chronic urticaria cases.
METHODS: Differences in clinical and laboratory parameters among AIU, PU and CIU groups were examined. AIU was diagnosed if the basophil CD63 assay was positive. Demographic data, severity of symptoms and association with allergic and autoimmune diseases were analysed by the aid of a questionnaire. Immunoassays were carried out and the effectiveness of therapy was also investigated.
RESULTS: Concerning the urticaria score, AIU patients had significantly higher total urticaria scores than patients with CIU (p = 0.013), dermatographic urticaria (p = 0.05) or cholinergic urticaria (p = 0.038). Between CIU and dermatographic urticaria and between CIU and cholinergic urticaria patients, we found insignificant differences in the urticaria score (p = 0.707 and p = 0.336, respectively). AIU was more frequently associated with autoimmune diseases in the personal history (p < 0.001) and with other types of urticaria in the family history (p < 0.001). Also, anti-thyroid antibodies were more frequently detected in the AIU group. Antihistamine therapy was less effective in the AIU group (12.8%) than in the PU (70.3%) and CIU groups (68.6%), but there were no significant differences between the CIU and PU groups regarding the effectiveness of antihistamine therapy.
CONCLUSION: The autoimmune subgroup represents the most severe form of chronic urticaria. On the other hand, there were no significant differences between the CIU and PU groups neither in urticaria scores nor in response to antihistamine therapy. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579280     DOI: 10.1159/000103995

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  6 in total

Review 1.  Urticaria.

Authors:  Pavel Kolkhir; Ana M Giménez-Arnau; Kanokvalai Kulthanan; Jonny Peter; Martin Metz; Marcus Maurer
Journal:  Nat Rev Dis Primers       Date:  2022-09-15       Impact factor: 65.038

2.  Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria.

Authors:  Vippan Goyal; Anu Gupta; Onam Gupta; Dhruvendra Lal; Manharan Gill
Journal:  J Clin Diagn Res       Date:  2017-03-01

3.  Evaluation of autologous serum skin test and skin prick test reactivity to house dust mite in patients with chronic spontaneous urticaria.

Authors:  Zhiqiang Song; Zhifang Zhai; Hua Zhong; Ziyuan Zhou; WenChieh Chen; Fei Hao
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

4.  Influence of initial treatment modality on long-term control of chronic idiopathic urticaria.

Authors:  Sujeong Kim; Seunghee Baek; Bomi Shin; Sun-young Yoon; So Young Park; Taehoon Lee; Yoon Su Lee; Yun-Jeong Bae; Hyouk Soo Kwon; You Sook Cho; Hee-Bom Moon; Tae-Bum Kim
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

5.  Autologous Serum Skin Test versus Autologous Plasma Skin Test in Patients with Chronic Spontaneous Urticaria.

Authors:  Aysegul Alpay; Nilgün Solak Tekin; Ishak Özel Tekin; H Cevdet Altinyazar; Rafet Koca; Saniye Cınar
Journal:  Dermatol Res Pract       Date:  2013-07-09

6.  Basophil markers for identification and activation in the indirect basophil activation test by flow cytometry for diagnosis of autoimmune urticaria.

Authors:  Zehwan Kim; Bong Seok Choi; Jong Kun Kim; Dong Il Won
Journal:  Ann Lab Med       Date:  2016-01       Impact factor: 3.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.